STI-2798

N/A

Report date: 2023/03/19 13:26:33

Base Information

Drug NameSTI-2798

Drug Alias NameSTI-2798

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD38

TargetsLymphocyte differentiation antigen CD38

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSorrento Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A